Back to Search Start Over

Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project.

Authors :
Collatuzzo G
Visci G
Violante FS
Porru S
Spiteri G
Monaco MGL
Larese Fillon F
Negro C
Janke C
Castelletti N
De Palma G
Sansone E
Mates D
Teodorescu S
Fabiánová E
Bérešová J
Vimercati L
Tafuri S
Abedini M
Ditano G
Asafo SS
Boffetta P
Source :
Frontiers in immunology [Front Immunol] 2022 Sep 29; Vol. 13, pp. 986085. Date of Electronic Publication: 2022 Sep 29 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: The duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs).<br />Methods: We analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1 <superscript>st</superscript> dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses.<br />Results: A 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels.<br />Conclusions: Female gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Collatuzzo, Visci, Violante, Porru, Spiteri, Monaco, Larese Fillon, Negro, Janke, Castelletti, De Palma, Sansone, Mates, Teodorescu, Fabiánová, Bérešová, Vimercati, Tafuri, Abedini, Ditano, Asafo, Boffetta and Orchestra WP5 Working Group.)

Details

Language :
English
ISSN :
1664-3224
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
36248889
Full Text :
https://doi.org/10.3389/fimmu.2022.986085